Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

The therapeutic potential of the endocannabinoid system for Alzheimer's disease.

Karl T, Cheng D, Garner B, Arnold JC.

Expert Opin Ther Targets. 2012 Apr;16(4):407-20. doi: 10.1517/14728222.2012.671812. Epub 2012 Mar 27. Review.

PMID:
22448595
2.

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.

Karl T, Garner B, Cheng D.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160. doi: 10.1097/FBP.0000000000000247. Review.

PMID:
27471947
3.

The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.

Bisogno T, Di Marzo V.

Curr Pharm Des. 2008;14(23):2299-3305. Review.

PMID:
18781980
4.

Targeting the endocannabinoid system in Alzheimer's disease.

Koppel J, Davies P.

J Alzheimers Dis. 2008 Nov;15(3):495-504. Review.

5.

The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.

Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S.

J Alzheimers Dis. 2015;43(4):1115-36. doi: 10.3233/JAD-141635. Review.

PMID:
25147120
6.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x. Review.

7.

The endocannabinoid system and Alzheimer's disease.

Benito C, Núñez E, Pazos MR, Tolón RM, Romero J.

Mol Neurobiol. 2007 Aug;36(1):75-81. Epub 2007 Sep 5.

PMID:
17952652
8.

Cannabinoid receptors and endocannabinoids: evidence for new players.

Mackie K, Stella N.

AAPS J. 2006 Apr 28;8(2):E298-306. Review.

9.

Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

Pazos MR, Núñez E, Benito C, Tolón RM, Romero J.

Life Sci. 2004 Sep 3;75(16):1907-15. Review.

PMID:
15306158
10.

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D.

Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x. Review.

11.

New and emerging treatments for Alzheimer's disease.

Corbett A, Ballard C.

Expert Opin Emerg Drugs. 2012 Jun;17(2):147-56. doi: 10.1517/14728214.2012.675327. Epub 2012 Mar 23. Review.

PMID:
22439621
12.

The endocannabinoid system in chronic liver disease.

Zamora-Valdés D, Ponciano-Rodríguez G, Chávez-Tapia NC, Méndez-Sánchez N.

Ann Hepatol. 2005 Oct-Dec;4(4):248-54. Review.

PMID:
16432489
13.

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.

Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.

Expert Opin Ther Targets. 2011 Oct;15(10):1153-62. doi: 10.1517/14728222.2011.600691. Epub 2011 Jul 12. Review.

PMID:
21749267
14.

[Functional role of the endocannabinoid system in emotional homeostasis].

Marco EM, Viveros MP.

Rev Neurol. 2009 Jan 1-15;48(1):20-6. Review. Spanish.

15.

Update on the endocannabinoid system as an anticancer target.

Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M.

Expert Opin Ther Targets. 2011 Mar;15(3):297-308. doi: 10.1517/14728222.2011.553606. Epub 2011 Jan 19. Review.

PMID:
21244344
16.

Inflammation and aging: can endocannabinoids help?

Marchalant Y, Brothers HM, Wenk GL.

Biomed Pharmacother. 2008 Apr-May;62(4):212-7. doi: 10.1016/j.biopha.2008.02.004. Epub 2008 Mar 14. Review.

18.

Drug delivery strategies for Alzheimer's disease treatment.

Di Stefano A, Iannitelli A, Laserra S, Sozio P.

Expert Opin Drug Deliv. 2011 May;8(5):581-603. doi: 10.1517/17425247.2011.561311. Epub 2011 Mar 11. Review.

PMID:
21391862
19.

Potential immunotargets for Alzheimer's disease treatment strategies.

Fernández PL, Britton GB, Rao KS.

J Alzheimers Dis. 2013;33(2):297-312. doi: 10.3233/JAD-2012-121222. Review.

PMID:
23001712

Supplemental Content

Support Center